Comparing different doses of Dexmedetomidine (for neuroprotection) with respect to neurological recovery in patients with bleeding witihin Brai
Not Applicable
Completed
- Conditions
- Health Condition 1: O- Medical and Surgical
- Registration Number
- CTRI/2022/06/043119
- Lead Sponsor
- Department of Anaesthesia and Intensive Care
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 75
Inclusion Criteria
All patients in age group 18-65 years with good grade Aneurysmal SAH (Hunt & Hess grade-1 & 2 or WFNS grade-1 & 2), coming for Aneurysmal clipping or coiling
Exclusion Criteria
1. Patients with severe heart, lung, liver, kidney, or metabolic diseases
2. Patients who had severe bradycardia or acute or chronic arrhythmias at presentation
3. Poor grade Aneurysmal SAH (Hunt & Hess grade-3-5 and WFNS grade 3-5)
4. Known allergy to dexmedetomidine
5. Patients with known Psychiatric disorders
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the effects of different doses of Dexmedetomidine (0.2µg/kg & 0.5µg/kg) vs placebo on neurological outcome of Aneurysmal SAH patients at discharge, defined as a Modified Rankin Scale (mRS) score of 0â??2.Timepoint: At discharge
- Secondary Outcome Measures
Name Time Method Comparison of S100β protein and NSE (Neuron Specific Enolase) levels at Pre-op and Post op- 48hrs (Day 2) & Post-op Day 5.Timepoint: Immediate Preoperative, 48 hours post intervention, and postoperative Day 5;Evaluation of autoregulatory status changes and Delayed Cerebral Ischemia (DCI) of patient by trans-cranial dopplerTimepoint: Preoperatively, Postop Day 1-5 daily once;Extended Glasgow Outcome Scale scoreTimepoint: At 3 months post discharge;Observation of effect of DEX infusion on Peri-operative patient hemodynamics (Heart rate and MAP)Timepoint: At 5 min interval throughout intra-operative period